The label for Metformin Hydrochloride was updated on 2026-02-10 by the FDA to include a new boxed warning concerning lactic acidosis. This warning highlights the potential for serious adverse events, including death, hypothermia, hypotension, and resistant bradyarrhythmias, associated with metformin-associated lactic acidosis.
What this means
The addition of a boxed warning to the Metformin Hydrochloride label underscores the critical importance for healthcare professionals to recognize and manage the risk of lactic acidosis. This serious adverse event, identified through postmarketing cases, has been linked to severe outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning specifically notes that the onset of metformin-associated lactic acidosis is often subtle, which necessitates a high index of suspicion from clinicians. This update reinforces the need for careful patient selection, ongoing monitoring, and adherence to prescribing information to mitigate the potential for this life-threatening complication.
Source
The information regarding this label revision was sourced from the FDA, with the update effective 2026-02-10, and is detailed on dailymed.nlm.nih.gov.